Faced with the encroaching threats of patent expirations and generics, biopharma companies in 2024 invested 33% more in licensing deals, on average, than in 2023 with an eye toward enriching their ...

A man who took part in a clinical trial for the development of a Covid vaccine has lashed out at the lingering effects.

A Brisbane man who took part in the University of Queensland’s aborted Covid vaccine trial is still returning “false positive” HIV tests four years later.

The committee voted along party lines Tuesday, with 14 Republicans voting to advance Kennedy in front of the Senate and 13 ...

COVID-19 has impacted nearly every aspect of life. Although tens of thousands of cases continue to occur each week, the world ...

Novavax Inc is a clinical-stage vaccine company. It is engaged in the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants.

Novavax (NVAX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

In the most recent trading session, Novavax (NVAX) closed at $8.45, indicating a +0.24% shift from the previous trading day. Health and pharmaceutical stocks — including Moderna (MRNA), Pfizer ...

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced progress in Q4 2024 advancing its corporate growth strategy through ...

Back in November 2023, pharmaphorum travelled to Uppsala, Sweden, for a Novavax press conference, the company celebrating a decade of doing what it does best: vaccines. From COVID-19 to malaria ...